Yeni Kuşak Antikoagülan ve Antiagregan İlaçlar ve Etki Mekanizmaları
Özet
Trombositlerin agregasyonu hayati önem taşıyan fizyolojik bir olaydır. Ancak bazı durumlarda patolojik bir hadiseye dönüşebilir. Bu tür durumların tedavisinde ve sonrasındaki takiplerinde antiagregan ve antikoagülan ilaçlar kullanılmaktadır. Bu ilaçlar bir takım patolojilere yol açan veya yol açabilecek pıhtılaşmaları engellerken kanamaya yatkınlık oluşturmaktadırlar.
Aggregation of platelets is a vital physiological event. However, in some cases it can turn into a pathological event. Antiaggregant and anticoagulant drugs are used in the treatment and follow-up of such conditions. While these drugs prevent clotting that leads to or may lead to certain pathologies, they also create a tendency to bleed.
Referanslar
Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. The Lancet. 2015;386(9990):281-91.
Hankey GJ. Anticoagulant therapy for patients with ischaemic stroke. Nature Reviews Neurology. 2012;8(6):319-28.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England journal of medicine. 2009;361(12):1139-51.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2011;365(11):981-92.
Diener H-C, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY, et al. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. The Lancet Neurology. 2012;11(3):225-31.
Connolly SJ, Eikelboom J, Joyner C, Diener H-C, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. New England Journal of Medicine. 2011;364(9):806-17.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011;365(10):883-91.
Referanslar
Mega JL, Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. The Lancet. 2015;386(9990):281-91.
Hankey GJ. Anticoagulant therapy for patients with ischaemic stroke. Nature Reviews Neurology. 2012;8(6):319-28.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England journal of medicine. 2009;361(12):1139-51.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2011;365(11):981-92.
Diener H-C, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY, et al. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. The Lancet Neurology. 2012;11(3):225-31.
Connolly SJ, Eikelboom J, Joyner C, Diener H-C, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. New England Journal of Medicine. 2011;364(9):806-17.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011;365(10):883-91.
